• Drug: lubiprostone
  • Manufacturer: misc

  • Route of Administration: Oral

  • Site of Care: Outpatient

  • Approved Indication:

    • treatment of irritable bowel syndrome with constipation in women 18 years of age and older
    • treatment of chronic idiopathic constipation in adults
    • treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not required frequent opioid dose escalation
  • Disease: irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), opioid-induced constipation (OIC)

  • Therapeutic Area: Gastroenterology

  • Enrollment Form Link: N/A

  • Phone Number: N/A

  • Fax Number: N/A

  • Product Website: N/A